Results 221 to 230 of about 90,574 (284)

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7237-7246, August 2026.
ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin   +6 more
wiley   +1 more source

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7247-7256, August 2026.
ABSTRACT Aims This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m2 and at least one obesity‐related complication) or obesity (BMI ≥ 30 kg/m2), without diabetes, using data ...
Wojciech Michalak   +7 more
wiley   +1 more source

Reseñas

open access: yesOASIS, 2009
Revista OASIS
doaj  

A STEP IN STONE. ONTOLOGIES OF PODOMORPHIC PETROGLYPHS IN SOUTHERN SCANDINAVIAN BRONZE AGE

open access: yesOxford Journal of Archaeology, Volume 45, Issue 3, Page 330-348, August 2026.
Summary During the Bronze Age, a particular type of podomorphic petroglyph was produced on the outcrops by the sea in southern Scandinavia. In this text, their distribution, organization and articulation are analyzed in the Mälaren region of central‐eastern Sweden.
Fredrik Fahlander
wiley   +1 more source

Home - About - Disclaimer - Privacy